Navigation Links
DSM Joins International Response to Flooding in Australia
Date:1/27/2011

PARSIPPANY, N.J., Jan. 27, 2011 /PRNewswire/ -- Significant flooding occurred in many areas of Queensland during late December 2010 and early January 2011.  Thousands of residents were affected.  A disaster relief appeal, the 'Premier's Disaster Relief Appeal', was launched on 29 December 2010, by Premier of Queensland, Anna Bligh.  DSM recognizes the efforts of Queenslanders who pitched in to help their fellow citizens clean-up in the wake of the floods and help families in need, many of whom lost everything.  

In May of 2010 DSM announced the signing of agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.  Currently under construction the facility will be located on the Princess Alexandra Hospital Campus, 5.5 kilometers from the center of Brisbane. Karen King, President of DSM Biologics commented, "We are extremely concerned about the effects of the severe flooding in Queensland and the need for support of those impacted."  

Professor Peter Gray, Director of the Australian Institute of Bioengineering & Nanotechnology which is based in Queensland, visited DSM soon after the flooding.  According to Professor Gray, "The relief appeal will make a significant difference by helping many in need as Queensland battles to recover from the flooding.  I am delighted to have DSM among our supporters."  Alexander Wessels, President and CEO, DSM Pharmaceutical Products, stated, "As a responsible corporate citizen around the world, DSM is committed to the communities in which we work and live. This is our humble gesture to aid those in need through the auspices of the Premier's appeal."

For more information about supporting the Premier's Disaster Relief Appeal, visit www.qld.gov.au/floods/  

DSM Pharmaceutical ProductsDSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticalproducts.com

DSM – the Life Sciences and Materials Sciences Company Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com For more information:DSMGuy TieneDirector, marketing and Communicationstel. +1 973 257 8160guy.tiene@dsm.com  DSM Forward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.


'/>"/>

SOURCE DSM Pharmaceutical Products
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampac Fine Chemicals President Aslam Malik Joins SOCMAs Board of Governors; Industry Veteran Adds Significant Experience to Board
2. Former FDA Commissioner Joins Bexion Pharmaceuticals Board
3. Catherine Derasp Joins PharmaNet as Vice President, Clinical Operations
4. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as COO
5. Joseph Perrone Joins SRI International to Direct Molecular Diagnostics and Rare and Neglected Diseases Group
6. Joseph J. LaRosa Joins Nycomed US Inc.
7. Timothy T. Goodnow, Ph.D., Joins Sensors for Medicine and Science, Inc. Board of Directors
8. Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
9. LitePoint Joins Continua Health Alliance
10. Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors
11. Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Global Endoscopy Market is poised to grow ... reach approximately $47.6 billion by 2025. This industry ... segments on global as well as regional levels presented in the ...
(Date:2/23/2017)... YORK , February 23, 2017 ... in the United States . According to ... the cannabis industry is expected to create 283,422 jobs by ... percent compounded over the next four years. The accelerating pace ... drives the growth of legal cannabis market, which will further ...
(Date:2/23/2017)... 23, 2017 Persistence Market ... global market for intraoperative imaging, excerpts from which ... US$ 513.9 million. According to the report, the ... the grounds of increasing adoption of minimally-invasive surgeries ... diagnostic imaging for neurosurgeries. The world,s leading medical ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... , ... Curemark, LLC announced today that the Blüm Study, a Phase 3 ... with Autism, is now enrolling at three new sites. These new sites are in ... , “There are currently no approved drugs that address the core symptoms of autism,” ...
(Date:2/22/2017)... Setauket, New York (PRWEB) , ... February 22, ... ... main floor entrance and lobby of a new healthcare contact center in Georgia, ... results. , One of the nation’s largest healthcare systems recently invested $51 million ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... treatment to the thousands of individuals who have recently fallen victim to America’s opioid ... in Orange County, California, where they are free from the shame, stigma, and ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with diabetes ... emergency room, fewer hospital admissions, and better blood pressure and glycemic control, a ... The study can be found here . , The study comes as ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its ... Dr. Steven H. Rauchman, practicing at North Valley Eye Medical Group in Mission ... premise liability and other personal injury cases. These injuries have a major impact ...
Breaking Medicine News(10 mins):